The decision by President Trump to withdraw from the Paris Accord was one of the biggest headlines this past week. Trump said that the primary reason for doing this was because he felt the US was getting the short end of the stick. He added that the country’s economy was going to suffer if they agreed to the current terms. Nick Akins is the CEO of American Electric Power. He said that he was not very pleased with the decision. He noted that the president said he was willing to renegotiate better terms and that was good news.
Many Republicans continue to oppose climate change. One Republican mayor in Indiana was not too pleased with Trump’s decision. Mayor James Brainard pointed to the increasing intensity and frequency of storms in the area when he was asked how climate change was affecting the area. He mentioned how the mayors of the country had united to sign the US Conference of Mayors Climate Protection Agreement. The mayors agreed to reduce the carbon emissions in their respective cities to curb the changes that were happening to the environment.
Clay Siegall is the co-founder, chief executive officer, and chairman of Seattle Genetics. The drug manufacturer was started in 1998. It is based in Seattle. Siegall is responsible for managing the company’s capital as the CEO. He was involved with cancer research centers such as the National Institute of Health, the Bristol-Myers Squibb Pharmaceutical Research Institute, and the National Cancer Institute in his career.
Siegall has been asked to serve on the boards of different companies and organizations in the medical field due to his expertise. He is the director of the Washington Biotechnology and Biomedical Association and Alder Biopharmaceuticals. Siegall received a Pierce award for his research on targeted toxins in 1995. Siegall is a member of the editorial board of several scientific journals. He serves as a member of the Board of Scientific Counselors for the Cancer Treatment Research Foundation. Siegall is the author of more than fifty scientific papers. He holds nine patents for innovations in cancer treatment and prevention.